- Home
- OTLK vs BCYC Comparison
OTLK vs BCYC Comparison
Compare OTLK & BCYC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | OTLK | BCYC |
|---|---|---|
| Founded | 2010 | 2009 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 249.6M | 291.8M |
| IPO Year | 2016 | 2019 |
Fundamental Metrics
Financial Performance| Metric | OTLK | BCYC |
|---|---|---|
| Price | $0.52 | $3.53 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 4 | 9 |
| Target Price | $5.03 | ★ $9.50 |
| AVG Volume (30 Days) | ★ 3.8M | 483.4K |
| Earning Date | 08-14-2026 | 11-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 55.91 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $8,146,123.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $6,355.64 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.16 | $3.33 |
| 52 Week High | $2.54 | $9.08 |
Technical Indicators
Market Signals| Indicator | OTLK | BCYC |
|---|---|---|
| Relative Strength Index (RSI) | 40.37 | 44.13 |
| Support Level | $0.40 | $3.33 |
| Resistance Level | $0.72 | $3.99 |
| Average True Range (ATR) | 0.05 | 0.19 |
| MACD | 0.01 | -0.00 |
| Stochastic Oscillator | 50.19 | 18.70 |
Price Performance
Historical ComparisonAbout OTLK Outlook Therapeutics Inc.
Outlook Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing ONS-5010, a monoclonal antibody, or mAb, for various ophthalmic indications. The Company have received marketing authorization for an ophthalmic formulation of ONS-5010/LYTENAVA (bevacizumab-gamma) for use in treating wet age-related macular degeneration, or wet AMD, in the European Union, and United Kingdom. The product pipeline includes ONS-5010/LYTENAVA, which is in total eight NORSES; ONS-5010 Clinical Progress, Unmet Patient Needs, New Ophthalmic Anti-VEGF, and Potential First Line Therapy.
About BCYC Bicycle Therapeutics plc
Bicycle Therapeutics PLC is a clinical-stage biopharmaceutical company developing a novel class of medicines which are referred to as Bicycles. The Bicycles are synthetic short peptides constrained to form two loops that stabilize their structural geometry. Its initial internal programs are focused on oncology indications with high unmet medical needs. The company's product candidate, BT1718, is a Bicycle Toxin Conjugate, or BTC. The company has two segments: the United Kingdom and the United States. It derives maximum revenue from United Kingdom.